Captor Therapeutics S.A. Total Liabilities

Latest as of September 2025: zł11.27 Million PLN ≈ $3.10 Million USD

Captor Therapeutics S.A. total liabilities. Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has total liabilities worth zł11.27 Million PLN (≈ $3.10 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Captor Therapeutics S.A. liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Captor Therapeutics S.A. (2017–2024)

Total liabilities of Captor Therapeutics S.A. from 2017 to 2024. This chart illustrates how Captor Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data.

Captor Therapeutics S.A. Competitors by Total Liabilities

The table below lists competitors of Captor Therapeutics S.A. ranked by their total liabilities.

Company	Country	Total Liabilities
Bflysoft Co. Ltd. KQ:148780	Korea	₩3.74 Billion
Xavis Co. Ltd KQ:254120	Korea	₩11.92 Billion
Jetway Information Co Ltd TWO:6161	Taiwan	NT$458.01 Million
Outcrop Gold Corp V:OCG	Canada	CA$579.42K
DTF Tax Free Income Closed Fund NYSE:DTF	USA	$2.92 Million
Bioton S.A. WAR:BIO	Poland	zł170.59 Million
GrandTech C.G. Systems TWO:6123	Taiwan	NT$1.90 Billion
Polar Capital Technology Trust LSE:PCT	UK	GBX123.44 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Captor Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Captor Therapeutics S.A. balance sheet assets.

Liquidity & Leverage Metrics

Captor Therapeutics S.A. Total Liabilities Ratios Explained

Captor Therapeutics S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.13	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.34	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.25	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Captor Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Captor Therapeutics S.A. (2017–2024)

The table below shows the annual total liabilities of Captor Therapeutics S.A. from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	zł23.02 Million ≈ $6.34 Million	-17.99%
2023-12-31	zł28.07 Million ≈ $7.73 Million	+68.33%
2022-12-31	zł16.68 Million ≈ $4.59 Million	-13.76%
2021-12-31	zł19.34 Million ≈ $5.32 Million	-27.79%
2020-12-31	zł26.78 Million ≈ $7.37 Million	+27.42%
2019-12-31	zł21.02 Million ≈ $5.79 Million	+43.68%
2018-12-31	zł14.63 Million ≈ $4.03 Million	+193.78%
2017-12-31	zł4.98 Million ≈ $1.37 Million	--

About Captor Therapeutics S.A.

WAR:CTX Poland Biotechnology

Market Cap

$80.35 Million

zł291.96 Million PLN

Market Cap Rank

#19851 Global

#160 in Poland

Share Price

zł53.00

Change (1 day)

-1.30%

52-Week Range

zł44.10 - zł87.60

All Time High

zł202.00